Viking Therapeutics
Stock
Stock
ISIN: US92686J1060
Ticker: VKTX
US92686J1060
VKTX
Price
Price
CHART BY
Frequently asked questions
What is Viking Therapeutics's market capitalization?
The market capitalization of Viking Therapeutics is $4.71B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Viking Therapeutics?
Viking Therapeutics's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.937. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Viking Therapeutics's stock?
Currently, 14 analysts cover Viking Therapeutics's stock, with a consensus target price of $112.14. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Viking Therapeutics?
Viking Therapeutics's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$133.66M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Viking Therapeutics?
Viking Therapeutics has a free cash flow of -$74.25M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Viking Therapeutics have, and what sector and industry does it belong to?
Viking Therapeutics employs approximately 27 people. It operates in the Health Care sector, specifically within the Pharmaceuticals: Major industry.
What is the free float of Viking Therapeutics's shares?
The free float of Viking Therapeutics is 108.05M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $4.71B
- EPS (TTM)
- -$0.937
- Free Float
- 108.05M
- EBITDA (TTM)
- -$133.66M
- Free Cashflow (TTM)
- -$74.25M
Pricing
- 1D span
- $39.73$49.68
- 52W span
- $17.24$99.38
Analyst Ratings
The price target is $112.14 and the stock is covered by 14 analysts.
Buy
14
Hold
0
Sell
0
Information
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
- Employees
- 27
- Industries
- Pharmaceuticals: Major
- Sector
- Health Care
Identifier
- ISIN
- US92686J1060
- Primary Ticker
- VKTX